Take the necessary steps to understand your condition and to seek the best treatment options

FDA approves faricimab for treatment of wet AMD and DME

Faricimab will be the first and only FDA-approved medicine targeting two distinct pathways, Ang-2 and VEGF-A, involved in retinal diseases and may cause vision loss. To se... Read More >

DRCR Network releases new data on Anti-VEGF response for diabetic macular edema
LAS VEGAS — For patients with diabetic macular edema, long-term response to vascular endothelial growth-factor (VEGF) inhibitors can be predicted after just three injections, according to a post hoc... Read More >

Our Mission
Our mission at the Angiogenesis Foundation is to improve health globally, through education and advocacy, and empower patients to take an active role in fighting vision loss. We work with DME patients, their advocates and healthcare providers around the world to disseminate knowledge about anti-VEGF treatments for DME in order to improve patient outcomes.
Find a Retinal Specialist

-- Or --
Media Updates